吸収不良症候群市場：治療、疾患タイプ、エンドユーザー別-2025-2030年の世界予測

吸収不良症候群市場は、2023年に23億4,000万米ドルと評価され、2024年には24億9,000万米ドルに達すると予測され、CAGR 5.66％で成長し、2030年には34億5,000万米ドルに達すると予測されています。

吸収不良症候群には、腸が食物から栄養素、ビタミン、ミネラルを十分に吸収できないことを特徴とするさまざまな疾患が含まれます。この症候群への対処の必要性は、深刻な栄養不足を引き起こす可能性があることから強調されており、診断および治療オプションに対する需要の高まりにつながっています。その用途はヘルスケア部門に及び、特に胃腸健康製品、栄養補助食品、医療診断に重点が置かれています。主なエンドユーザーには、吸収不良に関連する症状の診断、治療、管理を行う病院、診療所、専門医療センターが含まれます。吸収不良症候群管理市場は主に、胃腸障害の有病率の上昇、栄養不足に陥りやすい人口の高齢化、消化器の健康に関する意識の高まりによって牽引されています。診断ツールや治療オプションの技術的進歩は、市場成長にとって有利な機会をもたらします。例えば、早期診断のための高度な画像診断技術や非侵襲的検査法の開発は重要です。また、特定の欠乏症に対応するために設計された栄養補助食品に対する需要の急増も成長を支えています。しかし、市場開拓は、治療費の高騰、新興国地域での認識不足、ヘルスケア・インフラの未整備といった大きな課題に直面しています。さらに、この症候群を正確に診断することの複雑さがタイムリーな治療を妨げ、市場の勢いを阻害しています。この市場では、特に食事管理と薬物療法を統合した包括的な治療レジメンの策定において、技術革新と研究の機会が豊富にあります。企業はまた、より利用しやすく費用対効果の高い診断ソリューションへの投資からも利益を得ることができます。市場の進化に伴い、最先端の研究、製品開発、患者教育イニシアチブを含む学際的アプローチが非常に有利であることが証明されよう。潜在的な市場セグメントを開拓し、成長を促進するための戦略的な動きとして、診断と治療へのアクセス性を高めるためのヘルスケアプロバイダーとの連携強化が推奨されます。

市場力学：急速に進化する吸収不良症候群市場の主要市場インサイトを公開

吸収不良症候群市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 乳糖不耐症の消費者の増加
  • 吸収不良症候群に対する政府の積極的な取り組みと啓発キャンペーン
  • セリアック病などの消化器系疾患の増加
• 市場抑制要因
  • 適切なヘルスケアインフラの欠如
• 市場機会
  • 吸収不良症候群を治療するための規制当局の承認と臨床試験の増加
  • 新薬への投資と開発
• 市場の課題
  • 厳しい安全規制と製品回収

ポーターのファイブフォース：吸収不良症候群市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：吸収不良症候群市場における外部からの影響の把握

外部マクロ環境要因は、吸収不良症候群市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析吸収不良症候群市場における競合情勢の把握

吸収不良症候群市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス吸収不良症候群市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、吸収不良症候群市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨吸収不良症候群市場における成功への道筋を描く

吸収不良症候群市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 乳糖不耐症の消費者の増加
    • 吸収不良症候群に対する政府の好ましい取り組みと啓発キャンペーン
    • セリアック病やその他の消化器疾患などの原因疾患の発生率が増加
  • 抑制要因
    • 適切なヘルスケアインフラの欠如
  • 機会
    • 治療に関する規制当局の承認と臨床試験の増加吸収不良症候群
    • 新薬への投資と開発
  • 課題
    • 厳格な安全規則と製品リコール
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 吸収不良症候群市場治療別

• 抗炎症薬
• 抗生物質
• 下痢止め薬
• グルテンフリーダイエット
• 栄養補助食品
• プロテアーゼとリパーゼのサプリメント

第7章 吸収不良症候群市場：疾患タイプ別

• 嚢胞性線維症
• 乳糖不耐症
• スプルー

第8章 吸収不良症候群市場：エンドユーザー別

• 学術調査機関
• 病院
• 栄養クリニック
• 製薬会社

第9章 南北アメリカの吸収不良症候群市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の吸収不良症候群市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの吸収不良症候群市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbvie Inc.
• Ache Laboratorios Farmaceuticos S.A.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Baxter International Inc.
• Bayer AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Koninklijke Philips N.V.
• Merck & Co., Inc.
• Novartis AG
• Perrigo Company PLC
• Pfizer Inc.
• Sanofi S.A.
• Tillotts Pharma AG

LIST OF FIGURES

• FIGURE 1. MALABSORPTION SYNDROME MARKET RESEARCH PROCESS
• FIGURE 2. MALABSORPTION SYNDROME MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MALABSORPTION SYNDROME MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MALABSORPTION SYNDROME MARKET DYNAMICS
• TABLE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTIDIARRHEAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY GLUTEN-FREE DIET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PROTEASE & LIPASE SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY LACTOSE INTOLERANCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY SPRUE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITION CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 34. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 106. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 118. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 121. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

The Malabsorption Syndrome Market was valued at USD 2.34 billion in 2023, expected to reach USD 2.49 billion in 2024, and is projected to grow at a CAGR of 5.66%, to USD 3.45 billion by 2030.

Malabsorption Syndrome encompasses a range of disorders characterized by the intestine's inability to adequately absorb nutrients, vitamins, and minerals from food. The necessity of addressing this syndrome is underscored by its potential to cause severe nutritional deficiencies, leading to an increased demand for diagnostics and treatment options. Its applications span the healthcare sector, particularly focusing on gastrointestinal health products, dietary supplements, and medical diagnostics. Key end-users include hospitals, clinics, and specialized medical centers that diagnose, treat, and manage malabsorption-related conditions. The market for Malabsorption Syndrome management is primarily driven by the rising prevalence of gastrointestinal disorders, aging populations more prone to nutrient deficiencies, and increasing awareness regarding digestive health. Technological advancements in diagnostic tools and treatment options present lucrative opportunities for market growth. For instance, the development of advanced imaging techniques and non-invasive testing methods for early diagnosis is critical. Growth is also supported by a surge in demand for nutritional supplements designed to counter specific deficiencies. However, market expansion faces significant challenges, such as high treatment costs, lack of awareness in developing regions, and inadequate healthcare infrastructure. Furthermore, the complexity of accurately diagnosing the syndrome can impede timely treatment, hindering market momentum. Innovation and research opportunities abound within this market, especially in formulating comprehensive treatment regimens that integrate dietary management with pharmacotherapy. Companies can also benefit from investing in more accessible and cost-effective diagnostic solutions. With the market's evolving nature, a multidisciplinary approach encompassing cutting-edge research, product development, and patient education initiatives could prove highly advantageous. Strengthening collaborations with healthcare providers to enhance diagnosis and treatment accessibility is recommended as a strategic move to tap into potential market segments and foster growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Malabsorption Syndrome Market

The Malabsorption Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of lactose intolerance consumers
  • Favorable government initiatives and awareness campaigns for malabsorption syndrome
  • Growing incidences of cause disorders such as celiac disease and other digestive diseases
• Market Restraints
  • Lack of proper healthcare infrastructure
• Market Opportunities
  • Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
  • Investments and development of novel medicines
• Market Challenges
  • Stringent safety rules and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Malabsorption Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Malabsorption Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Malabsorption Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Malabsorption Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Malabsorption Syndrome Market

A detailed market share analysis in the Malabsorption Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Malabsorption Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Malabsorption Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Malabsorption Syndrome Market

A strategic analysis of the Malabsorption Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Malabsorption Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Ache Laboratorios Farmaceuticos S.A., AstraZeneca PLC, Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Koninklijke Philips N.V., Merck & Co., Inc., Novartis AG, Perrigo Company PLC, Pfizer Inc., Sanofi S.A., and Tillotts Pharma AG.

Market Segmentation & Coverage

This research report categorizes the Malabsorption Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents, Gluten-Free Diet, Nutritional Supplements, and Protease & Lipase Supplements.
• Based on Disease Type, market is studied across Cystic Fibrosis, Lactose Intolerance, and Sprue.
• Based on End-user, market is studied across Academic & Research Institutes, Hospitals, Nutrition Clinics, and Pharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of lactose intolerance consumers
    • 5.1.1.2. Favorable government initiatives and awareness campaigns for malabsorption syndrome
    • 5.1.1.3. Growing incidences of cause disorders such as celiac disease and other digestive diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of proper healthcare infrastructure
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
    • 5.1.3.2. Investments and development of novel medicines
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent safety rules and product recalls
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Malabsorption Syndrome Market, by Treatment

• 6.1. Introduction
• 6.2. Anti-Inflammatory Drugs
• 6.3. Antibiotics
• 6.4. Antidiarrheal Agents
• 6.5. Gluten-Free Diet
• 6.6. Nutritional Supplements
• 6.7. Protease & Lipase Supplements

7. Malabsorption Syndrome Market, by Disease Type

• 7.1. Introduction
• 7.2. Cystic Fibrosis
• 7.3. Lactose Intolerance
• 7.4. Sprue

8. Malabsorption Syndrome Market, by End-user

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Hospitals
• 8.4. Nutrition Clinics
• 8.5. Pharmaceutical Companies

9. Americas Malabsorption Syndrome Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Malabsorption Syndrome Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Malabsorption Syndrome Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie Inc.
• 2. Ache Laboratorios Farmaceuticos S.A.
• 3. AstraZeneca PLC
• 4. Bausch Health Companies Inc.
• 5. Baxter International Inc.
• 6. Bayer AG
• 7. Gilead Sciences, Inc.
• 8. GlaxoSmithKline PLC
• 9. Koninklijke Philips N.V.
• 10. Merck & Co., Inc.
• 11. Novartis AG
• 12. Perrigo Company PLC
• 13. Pfizer Inc.
• 14. Sanofi S.A.
• 15. Tillotts Pharma AG